Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma
Sven de Vos(University of California, Los Angeles), John P. Leonard(New York University), Richard R. Furman(Cornell University), Nina D. Wagner‐Johnston(Sidney Kimmel Comprehensive Cancer Center), Steven Coutré(Georgetown University), Marshall T. Schreeder(Clearview Cancer Institute), Wayne R. Godfrey(Dana-Farber Cancer Institute), Nathan Fowler(Repligen (United States)), Jacqueline C. Barrientos(Mount Sinai Medical Center), Thomas E. Boyd(University of Vermont), Yeonhee Kim(Lyell Immunopharma (United States)), Ian W. Flinn(Tennessee Oncology), Ralph V. Boccia(Center for Cancer and Blood Disorders), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center)
Cited by 19
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k